Anesiva — Merger or Acquisition (September 2009)
28 slides from Anesiva's merger presentation, Sep 17, 2009
Slide 1: Investment Presentation
Investment Presentation August 2009 Exhibit 99.1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan,
Slide 3: Forward-Looking Statements (con't)
Forward-Looking Statements (con’t) Additional Information and Where to Find It The Company has a filed a preliminary proxy statement and intends to file a definitive proxy statement with the Securities and Exchange Commission (the "SEC") in connection with the Merger. Investors and security holders
Slide 4: Arcion/Anesiva Investment Overview Aug 2009
Arcion/Anesiva Investment Overview Aug 2009 NASDAQ Company Private Company NASDAQ Company
Slide 5: Financing Description
Financing Description $20 + MM private placement (PIPE) InterWest & CMEA have signed non-binding letters of intent for $10MM To close immediately prior to the consummation of the merger
Slide 6: Investment Opportunity
Investment Opportunity Targeted pain therapeutics – Directed at the site where pain signal originates – Avoids systemic side effects Late-stage programs to address large markets with unmet needs – Extensive safety and efficacy databases Virtual company (1) to maximize capital efficiency Seasoned man
Slide 7: Experienced Leadership Team
Experienced Leadership Team Michael Kranda, CEO Anesiva, Vulcan, OGS, Immunex James Campbell, M.D., CMO Founder of Arcion, Prof. Johns Hopkins Kerrie Brady, CBO Traxion, KMG Japan Inc., Entremed, Rhone Poulenc John Tran, VP Finance & CAO Anesiva, Medtronic, Kyphon, PwC Carlos Schuler, Ph.D., VP CMC
Slide 8: Experienced Advisory Team
Experienced Advisory Team William Houghton, M.D. Anesiva, Jazz, Orphan Medical, Abbott Cynthia McCormick, M.D. Regulatory, former FDA analgesic division head William Schmidt, Ph.D. Regulatory, clinical, Adolor, Renovis, Dupont, Merck Bruce Stouch, Ph.D. Biostatistics, expert in adaptive design
Slide 9: Pain Market: Large and Growing
Pain Market: Large and Growing Large U.S. prescription pain market – 25 million experience moderate-to-severe acute pain each year – 50 million suffer from chronic pain 9% annual market growth supported by: – Aging population – Longer survival times of patients with chronic conditions – Increased aw
Slide 10: Arcion Target Markets
Arcion Target Markets Arcion Drug U.S. Patients Estimated Drug Market Neuropathic Pain – - Painful diabetic neuropathy - Post-herpetic neuralgia - Morton’s neuroma ARC-4558 ARC-2022 ARC-4975 2.7 million 200,000 200,000 $2.2 billion Moderate-to-severe Osteoarthritis ARC-4975 3 million $4.0 billion Po
Slide 11: Late-stage, Diverse Pipeline
Late-stage, Diverse Pipeline (2) (2) (2) (2) ARC – 4975 is also known as Adlea
Slide 12: ARC-4558 Overview
ARC-4558 Overview Product description : – Clonidine 0.1% topical gel Mechanism-of-action : – Alpha-2 adrenergic receptor agonist – iGPCR and cAMP Key benefits – Administered locally to painful site – Rivals efficacy of oral treatments with reduced side effects – Does not anesthetize the skin MOA: In
Slide 13: Overview: ARC-4558 in Painful Diabetic Neuropathy
Overview: ARC-4558 in Painful Diabetic Neuropathy Product: – Topical clonidine gel for the management of PDN Market: – ~2.7 million patients in the U.S. (over $2 billion market) – Neuropathic pain market expected to grow to $9 billion in 2015 Product attributes: – Topical gel for easy application di
Slide 14: Cymbalta Phase Pain Relief Data
Cymbalta Phase 3 Pain Relief Data ~1 WEEK Baseline Scores 5.85 - 6.21 A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain - Wernicke JF et al, Neurology 2006;67;1411 - 1420
Slide 15: ARC-4558 Gel Provides Similar Pain Relief
ARC-4558 Gel Provides Similar Pain Relief ARC-4558 clinical studies Phase 2 – placebo controlled – PDN (CLO-023) ~1
Slide 16: Why Target The Skin?
Why Target The Skin? Adverse event Pregabalin n=76 300 mg/day Placebo n=70 Dizziness 27 (35.5%) 8 (11.4%) Somnolence 15 (19.7%) 2 (2.9%) Infection 11 (14.5%) 4 (5.7%) Peripheral edema 8 (10.5%) 1 (1.4%) Nausea 6 (7.9%) 6 (8.6%) Amblyopia 4 (5.3%) 1 (1.4%) Constipation 4 (5.3%) 0 (0.0%) Euphoria 4 (5
Slide 17: ARC-4558 Provides Level of Pain Relief that Rivals Oral Treatments
ARC-4558 Clinical Studies ARC-4558 Provides Level of Pain Relief that Rivals Oral Treatments Duloxetine Gabapentin Pregabalin ARC-4558 Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain . Quicilli. S. et al, BMC Neurology 9:6
Slide 18: ARC-4558 Development Plan
ARC-4558 Development Plan 505b2 strategy for registration filing Complete Phase 2b study – Double-blind, randomized, placebo-controlled study in PDN – End point: Change in pain from baseline (NPRS) at week 12 – Top-line results expected 2Q10 Seek partner Initiate Phase 3 study in 2010 (complete in 2
Slide 19: Overview: ARC-4975
Overview: ARC-4975 Product description – Highly purified capsaicin injection Mechanism-of-action – Disrupts nociceptors via action mediated by TRPV channel – No effect on other sensory fibers Key benefits – Highly selective – targets only pain fibers – Administered locally – Long lasting analgesic e
Slide 20: Capsaicin Knocks Out Pain Fibers Through TRPV
Capsaicin Knocks Out Pain Fibers Through TRPV 1 Simone et al Journal of Neuroscience, 1998, 18:8947-8959 Nerve fibers ( N ) Basement membrane ( B ) Vessels ( V )
Slide 21: Studies of ARC-4975 To Date
Studies of ARC-4975 To Date Indication Subjects $70M investment 12 x Phase 2 & 3 studies Efficacy observed in multiple indications No safety issues Post-Operative Pain Total Knee Replacement Bunionectomy Total Hip Replacement Arthroscopic Shoulder Cholecystectomy Hernia Neuropathic Pain Morton’s Neu
Slide 22: ARC-4975: Development Plan
ARC-4975: Development Plan Morton’s neuroma = shortest path to NDA – Build on prior positive Morton’s neuroma data package – Orphan designation granted Proof-of-concept in OA to open larger markets – Build on prior positive Osteoarthritis data package – Pilot novel, cost-efficient study design Partn
Slide 23: Overview: ARC-4975 in Morton's Neuroma
Overview: ARC-4975 in Morton’s Neuroma Product: – Localized capsaicin injection for Morton’s neuroma Market: – U.S. incidence = 200,000 patients per year Product attributes: – Local injection, long-acting (weeks – months) – Non-surgical intervention Development status: – Efficacy demonstrated in Pha
Slide 24: ARC-4975 for Osteoarthritis Pain
ARC-4975 for Osteoarthritis Pain Product: – Capsaicin injection for moderate-to-severe osteoarthritis Market: – 3 million patients with moderate-to-severe OA in joints – Underserved market with limited targeted options Product attributes: – Local injection, long-acting (weeks – months) Development s
Slide 25: ARC-4975 Post-operative Pain
ARC-4975 Post-operative Pain Product: – Single local application of capsaicin – Management of acute pain following surgery Market: – 3.7 million patients Product attributes: – Local injection, long-acting – Reduction of opioid use – Earlier patient ambulation Development status: – Completed 2 Phase
Slide 26: ARC-2022 for Post-herpetic Neuralgia
ARC-2022 for Post-herpetic Neuralgia Product: – Topical gel for treatment of post-herpetic neuralgia (PHN) Market: – Orphan indication – Approved topical product: Lidoderm patch ($800 M sales, patent exp. 2012) Product attributes: – Delivers active ingredient into skin without need for occlusive pat
Slide 27: Anesiva/Arcion Merger
Anesiva/Arcion Merger Merger agreement – Arcion to take over Anesiva listing and operate as a public company – Management teams to be blended Expected closing of the merger – Anesiva anticipates that the consummation of the merger will occur sometime in the fourth quarter of 2009, but we cannot pred
Slide 28: Arcion Value Proposition
Arcion Value Proposition Virtual company focused on pain therapeutics Multiple clinical programs underway Seasoned management team with deep knowledge of pain product development Near-term value inflection points – Clinical validation of lead program – Multiple product candidates that could provide